Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad collaboration between Daiichi Sankyo and AstraZeneca.
The post AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer appeared first on MedCity News.
